• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

A comparative study of intravenous labetalol VS intravenous Nitroglycerin in the treatment of hypertensive crises
Indian Heart J. 2022 Jun 3:S0019-4832(22)00097-9. doi: 10.1016/j.ihj.2022.06.001. Online ahead of print.ABSTRACTHypertensive crises is still a major public health problem, causing end organ damage like myocardial infarction, stroke, and renal failure. Labetalol and nitroglycerine are among the two most commonly used medicine to control the blood pressure, but there is no head to head comparison between these two medicines. This was a prospective randomized non-blinded study which included 50 patients of hypertensive crises, out which 25 patients received intravenous labetalol and 25 patients received intravenous nitroglyce...
Source: Indian Heart J - June 6, 2022 Category: Cardiology Authors: M O H A M M A D A Z H A R U D D I N Malik R E H A N Ahmad M U J A H I D Beg R I Z W A N Ahmad Source Type: research

Classical prescription Dachuanxiong Formula delays nitroglycerin-induced pain response in migraine mice through reducing endothelin-1 level and regulating fatty acid biosynthesis
CONCLUSIONS: The present study revealed the anti-migraine effect of DCXF in migraine mice and provided insights into the mechanisms of DCXF-mediating anti-migraine treatment.PMID:35032586 | DOI:10.1016/j.jep.2022.114992
Source: Atherosclerosis - January 15, 2022 Category: Cardiology Authors: Chi Teng Vong Yulong Chen Zhejie Chen Caifang Gao Fengqing Yang Shengpeng Wang Yitao Wang Source Type: research

IMPROvE-CED Trial: Intracoronary Autologous CD34+ Cell Therapy for Treatment of Coronary Endothelial Dysfunction in Patients With Angina and Non-Obstructive Coronary Arteries
Conclusion: A single IC autologous CD34+ cell infusion was safe and may potentially be an effective disease-modifying therapy for microvascular CED in humans. Clinical Trial Registration: NCT03471611.PMID:34923853 | DOI:10.1161/CIRCRESAHA.121.319644
Source: Circulation Research - December 20, 2021 Category: Cardiology Authors: Michel T Corban Takumi Toya Diana P Albers Faten Sebaali Bradley Lewis John P Pearce Bois Rajiv Gulati Abhiram Prasad Patricia J Best Malcolm Bell Charanjit Rihal Megha Prasad Ali Ahmad Lilach O Lerman Mary L Solseth Jeffrey L Winters Allan B Dietz Amir L Source Type: research

The Current Role of Clevidipine in the Management of Hypertension
AbstractAcute hypertension, which may damage blood vessels, causes irreversible organ damage to the vasculature, central nervous system, kidney, and heart. Clevidipine, the first third-generation calcium channel antagonist approved by the Food and Drug Administration (FDA) in the past 20 years, is an ultra-short-acting calcium channel blocker that inhibits L-type calcium channels with high clearance and low distribution, can be rapidly metabolized into the corresponding inactive acid, and is rapidly hydrolyzed into inactive metabolites by esterase in arterial blood. Clevidipine is the same as nicardipine in that the main p...
Source: American Journal of Cardiovascular Drugs - September 2, 2021 Category: Cardiology Source Type: research

Haemodynamic effects of the nitroxyl donor cimlanod (BMS ‐986231) in chronic heart failure: a randomized trial
ConclusionIn patients with chronic HFrEF, the haemodynamic effects of cimlanod and NTG are similar. The effects of cimlanod may be explained by venodilatation and preload reduction without additional inotropic or lusitropic effects. Ongoing trials of cimlanod will further define its potential role in the treatment of heart failure.
Source: European Journal of Heart Failure - March 9, 2021 Category: Cardiology Authors: Ninian N. Lang, Faheem A. Ahmad, John G. Cleland, Christopher M. O'Connor, John R. Teerlink, Adriaan A. Voors, Jorg Taubel, Anke R. Hodes, Mohamed Anwar, Ravi Karra, Yasushi Sakata, Shiro Ishihara, Roxy Senior, Abhishek Khemka, Narayana G. P Tags: Research Article Source Type: research

Hemodynamic Effects of the Nitroxyl Donor Cimlanod (BMS ‐986231) in Chronic Heart Failure: A Randomized Trial
ConclusionIn patients with chronic HFrEF, the hemodynamic effects of cimlanod and NTG are similar. The effects of cimlanod may be explained by venodilatation and preload reduction without additional inotropic or lusitropic effects. Ongoing trials of cimlanod will further define its potential role in the treatment of heart failure.
Source: European Journal of Heart Failure - February 23, 2021 Category: Cardiology Authors: Ninian N. Lang, Faheem A. Ahmad, John G. Cleland, Christopher M. O'Connor, John R. Teerlink, Adriaan A. Voors, Jorg Taubel, Anke R. Hodes, Mohamed Anwar, Ravi Karra, Yasushi Sakata, Shiro Ishihara, Roxy Senior, Abhishek Khemka, Narayana G. P Tags: Research Article Source Type: research

Pages: 1  2